Prelude Therapeutics Inc
PRLDNasdaq
$4.20
↑ +0.5%Jul 17 close · end-of-day
Price
1Y↑ +412.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$346.6M
Enterprise Value
$265.0M
P/E
—
P/S
—
P/B
5.8
EV/EBITDA
—
PEG
—
FCF Yield
-12.6%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$77.8M
Free Cash Flow (TTM)
-$43.8M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-129.3%
ROIC
—
Debt / Equity
—
Net Cash
$81.6M
Return 1Y
+412.2%
Company profile
Prelude Therapeutics Incorporated focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
- CEO
- Krishna Vaddi
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 120
- Headquarters
- Delaware
- Website
- preludetx.com
Earnings
PRLD Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$4.6M—
Diluted EPS-$0.13↓ -69.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $7.0M | $12.1M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$58.8M | -$113.7M | -$123.5M | -$132.3M | -$139.7M | -$104.6M |
| Net income | -$56.9M | -$111.7M | -$115.4M | -$121.8M | -$127.2M | -$99.5M |
| Diluted EPS | — | -$2.43 | -$2.44 | -$2.02 | -$1.68 | -$1.29 |
| Operating cash flow | -$46.2M | -$83.5M | -$83.7M | -$107.1M | -$102.9M | -$56.3M |
| Free cash flow | -$46.8M | -$85.9M | -$86.7M | -$110.6M | -$103.7M | -$56.4M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | -1995.9% | -861.3% |
| Net margin | — | — | — | — | -1816.7% | -819.6% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $3.0M | — | $0.00 | — | $6.5M | — | $4.6M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$37.2M | -$34.4M | -$33.8M | -$34.6M | -$32.2M | -$20.4M | -$17.3M | -$14.2M |
| Net income | -$34.7M | -$32.3M | -$28.7M | -$32.1M | -$31.2M | -$19.7M | -$16.5M | -$10.4M |
| Diluted EPS | -$0.46 | -$0.43 | -$0.37 | -$0.42 | -$0.41 | -$0.26 | -$0.20 | -$0.13 |
| Operating cash flow | -$23.1M | -$27.3M | -$20.7M | -$34.2M | -$26.1M | -$19.1M | $23.1M | -$21.7M |
| Free cash flow | -$23.4M | -$27.4M | -$20.8M | -$34.3M | -$26.1M | -$19.1M | $23.1M | -$21.7M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | -1145.9% | — | — | — | -314.1% | — | -309.5% |
| Net margin | — | -1075.7% | — | — | — | -303.5% | — | -226.7% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-04-27 | RA CAPITAL MANAGEMENT, LLC | J | 1,407,000 | — | — | filing |
| 2026-04-21 | ORBIMED ADVISORS LLC | Buy | 1,689,189 | $4.44 | $7.5M | filing |
| 2026-04-21 | Bonita David P | Buy | 1,689,189 | $4.44 | $7.5M | filing |
| 2026-04-21 | ORBIMED ADVISORS LLC | Buy | 1,126,126 | $4.44 | $5.0M | filing |
| 2026-04-21 | Bonita David P | Buy | 1,126,126 | $4.44 | $5.0M | filing |
| 2025-10-04 | Huang Jane· President, CMO | Tax withholding | 3,355 | $1.47 | $4,931.85 | filing |
| 2025-10-04 | Huang Jane· President, CMO | Option exercise | 9,375 | — | — | filing |
| 2025-07-04 | Huang Jane· President, CMO | Tax withholding | 3,355 | $0.79 | $2,663.53 | filing |
| 2025-07-04 | Huang Jane· President, CMO | Option exercise | 9,375 | — | — | filing |
Latest 9 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.